<DOC>
	<DOCNO>NCT00237887</DOCNO>
	<brief_summary>A Phase III , Multicenter Study Efficacy Safety Adalimumab Treatment Subjects Moderate Severe Chronic Plaque Psoriasis</brief_summary>
	<brief_title>Efficacy Safety Adalimumab Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject age 18 old good health ( Investigator discretion ) recent stable medical history . Subject clinical diagnosis psoriasis least 6 month , moderate severe plaque psoriasis . Subject able willing selfadminister sc injection available qualified person ( ) administer sc injection Subject previously receive antiTNF therapy . Subject discontinue systemic therapy and/or topical therapy treatment psoriasis avoid UVB PUVA phototherapy Subject avoid excessive sun exposure Subject take require oral injectable corticosteroid Subject consider investigator , reason , unsuitable candidate study Female subject pregnant breastfeeding consider become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>adalimumab</keyword>
</DOC>